No profile data available.
Probi AB (publ) (PBBIF) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Lund, Sweden, with about 157 full-time employees.
It reported revenue of 627.69 million SEK for fiscal year 2023, up 1.5% from fiscal year 2022, and net income of 16.82 million SEK. In Q3 2024 (the quarter ended September 30, 2024) revenue was 143.71 million SEK, down 7.9% from a year before. Its market capitalization was $286.93 million as of January 29, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of January 29, 2026.
Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally.
Probi AB (publ) reported 627.69 million SEK in revenue for fiscal year 2023, up 1.5% from 618.29 million SEK in fiscal year 2022. In Q3 2024 revenue was 143.71 million SEK.
$286.93 million as of January 29, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Emergent BioSolutions Inc. (EBS), Silence Therapeutics plc (SLN), Contineum Therapeutics, Inc. (CTNM), Bicycle Therapeutics plc (BCYC).